# SFJ Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sfj-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Pleasanton, US
- Website: www.sfj-pharma.com
- Total disclosed funding: $45M
- Latest round: Series A (Mar 16, 2009)
- Investors on record: 2

## About

Based in California, US, and founded by Robert DeBenedetto (President and CEO) in 2009, SFJ (Strategic Funding and Joint-Development) Pharmaceuticals, Inc. also known as SFJ-NSCLC, operates as a pharmaceutical company that engages in the clinical development and registration of pharmaceutical products. In March 2009, the firm raised USD 45 million in series A financing co-led by Abingworth Management and Clarus Ventures, and in October 2013, it raised USD 30 million in venture funding led by new investor Clarus Ventures. The company is also backed by Blackstone.

The strategic funding and joint-development company provide risk capital, expertise, resources, and global reach for accelerated clinical development and registration of pharmaceutical products. The company through its partners in the biopharmaceutical industry, focuses on filling operational and funding gaps and maximizing the retained net present value (NPV) for late-stage partnerships. SFJ’s solution encompasses three key pillars: capital, expertise, and resources. SFJ brings multiple approvals in major markets, trial design and execution capabilities, and incremental headcount to support its collaborations. Additionally, the company offers global reach and manages contract research organizations (CROs) for full-service support.

## Funding rounds

- Series A, Mar 16, 2009, $45M — Abingworth, Clarus Ventures

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series A